Compare KYNB & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KYNB | PASG |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | 34 | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 26.0M |
| IPO Year | N/A | 2020 |
| Metric | KYNB | PASG |
|---|---|---|
| Price | $6.90 | $5.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 7.0K | ★ 58.4K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.35 |
| 52 Week High | $9.58 | $20.00 |
| Indicator | KYNB | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 50.45 |
| Support Level | $6.73 | $3.94 |
| Resistance Level | $7.42 | $8.94 |
| Average True Range (ATR) | 0.18 | 0.40 |
| MACD | 0.01 | 0.22 |
| Stochastic Oscillator | 39.55 | 90.30 |
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.